Aurora Investment Counsel’s Haemonetics HAE Stock Holding History

Aurora Investment Counsel’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.91M	Buy	25,501 +3,906	+18%	+$251K	0.98%	50
2026 Q1	$1.22M	Buy	+21,595	New	+$1.41M	0.68%	80
2022 Q4	–	Sell	-22,059	Closed	-$1.63M	–	115
2022 Q3	$1.63M	Sell	22,059 -9,466	-30%	-$680K	1.24%	14
2022 Q2	$2.06M	Buy	31,525 +73	+0.2%	+$4.32K	1.48%	3
2022 Q1	$1.99M	Sell	31,452 -697	-2%	-$37.9K	1.27%	5
2021 Q4	$1.71M	Buy	+32,149	New	+$1.96M	1.01%	30

Other funds holding HAE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Aurora Investment Counsel's HAE Position: Q2 2026 in Review

Aurora Investment Counsel increased its Haemonetics (HAE) stake by 18% in Q2 2026, buying an estimated $251K and bringing the position to 25,501 shares worth $1.91M. The position accounts for 0.98% of the portfolio, ranked #50.

Aurora Investment Counsel first reported a position in HAE in Q4 2021 and has held it in 6 quarters since. The position peaked at $2.06M in Q2 2022. 329 funds tracked by Wall St. Rank hold HAE as of Q2 2026.

Aurora Investment Counsel held 25,501 shares of Haemonetics worth $1.91M as of Q2 2026.
Aurora Investment Counsel bought 3,906 Haemonetics shares in Q2 2026, an estimated $251K.
Haemonetics made up 0.98% of Aurora Investment Counsel's portfolio in Q2 2026, its #50 holding.
Aurora Investment Counsel first reported a position in Haemonetics in Q4 2021 and has held it in 6 quarters since.
Aurora Investment Counsel's Haemonetics position peaked at $2.06M in Q2 2022.
329 funds tracked by Wall St. Rank held Haemonetics as of Q2 2026.

Based on Aurora Investment Counsel's 13F filing for Q2 2026, filed 10 Aug 2026.